These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28400467)

  • 1. Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study.
    Koitzsch U; Heydt C; Attig H; Immerschitt I; Merkelbach-Bruse S; Fammartino A; Büttner RH; Kong Y; Odenthal M
    J Clin Pathol; 2017 Aug; 70(8):725-728. PubMed ID: 28400467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.
    Darwanto A; Hein AM; Strauss S; Kong Y; Sheridan A; Richards D; Lader E; Ngowe M; Pelletier T; Adams D; Ricker A; Patel N; Kühne A; Hughes S; Shiffman D; Zimmermann D; Te Kaat K; Rothmann T
    BMC Cancer; 2017 May; 17(1):358. PubMed ID: 28532404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing.
    Zhong Q; Wagner U; Kurt H; Molinari F; Cathomas G; Komminoth P; Barman-Aksözen J; Schneider-Yin X; Rey JP; Vassella E; Rogel U; Diebold J; McKee T; Jochum W; Kashofer K; Hofman P; Zischka M; Moch H; Rechsteiner M; Wild PJ
    Pathol Res Pract; 2018 Jul; 214(7):957-963. PubMed ID: 29807778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens.
    Rathi V; Wright G; Constantin D; Chang S; Pham H; Jones K; Palios A; Mclachlan SA; Conron M; McKelvie P; Williams R
    Pathology; 2017 Jan; 49(1):75-82. PubMed ID: 27913044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical validation of a next generation sequencing testing panel.
    Lüsebrink J; Pieper M; Tillmann RL; Brockmann M; Schildgen O; Schildgen V
    Exp Mol Pathol; 2018 Jun; 104(3):170-174. PubMed ID: 29641993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel.
    Choudhary A; Mambo E; Sanford T; Boedigheimer M; Twomey B; Califano J; Hadd A; Oliner KS; Beaudenon S; Latham GJ; Adai AT
    BMC Med Genomics; 2014 Nov; 7():62. PubMed ID: 25395014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests.
    Aziz N; Zhao Q; Bry L; Driscoll DK; Funke B; Gibson JS; Grody WW; Hegde MR; Hoeltge GA; Leonard DG; Merker JD; Nagarajan R; Palicki LA; Robetorye RS; Schrijver I; Weck KE; Voelkerding KV
    Arch Pathol Lab Med; 2015 Apr; 139(4):481-93. PubMed ID: 25152313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
    Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
    Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
    Burghel GJ; Hurst CD; Watson CM; Chambers PA; Dickinson H; Roberts P; Knowles MA
    Biomed Res Int; 2015; 2015():478017. PubMed ID: 26351634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients.
    Heeke S; Hofman V; Long-Mira E; Lespinet V; Lalvée S; Bordone O; Ribeyre C; Tanga V; Benzaquen J; Leroy S; Cohen C; Mouroux J; Marquette CH; Ilié M; Hofman P
    Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29561830
    [No Abstract]   [Full Text] [Related]  

  • 11. Big data from small samples: Informatics of next-generation sequencing in cytopathology.
    Roy-Chowdhuri S; Roy S; Monaco SE; Routbort MJ; Pantanowitz L
    Cancer Cytopathol; 2017 Apr; 125(4):236-244. PubMed ID: 27918649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel framework for analyzing somatic copy number aberrations and tumor subclones for paired heterogeneous tumor samples.
    Xia H; Li A; Yu Z; Liu X; Feng H
    Biomed Mater Eng; 2015; 26 Suppl 1():S1845-53. PubMed ID: 26405956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory.
    Simen BB; Yin L; Goswami CP; Davis KO; Bajaj R; Gong JZ; Peiper SC; Johnson ES; Wang ZX
    Arch Pathol Lab Med; 2015 Apr; 139(4):508-17. PubMed ID: 25356985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories.
    Mendez P; Dang J; Kim JW; Lee S; Yoon JH; Kim T; Sailey CJ; Jablons DM; Kim IJ
    Int J Oncol; 2016 Jul; 49(1):235-42. PubMed ID: 27121194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
    Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
    Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance evaluation of the next-generation sequencing approach for molecular diagnosis of hereditary hearing loss.
    Sivakumaran TA; Husami A; Kissell D; Zhang W; Keddache M; Black AP; Tinkle BT; Greinwald JH; Zhang K
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1007-16. PubMed ID: 23525850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective quality management practices in routine clinical next-generation sequencing.
    de Abreu FB; Peterson JD; Amos CI; Wells WA; Tsongalis GJ
    Clin Chem Lab Med; 2016 May; 54(5):761-71. PubMed ID: 26872315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors.
    Goswami RS; Luthra R; Singh RR; Patel KP; Routbort MJ; Aldape KD; Yao H; Dang HD; Barkoh BA; Manekia J; Medeiros LJ; Roy-Chowdhuri S; Stewart J; Broaddus RR; Chen H
    Am J Clin Pathol; 2016 Feb; 145(2):222-37. PubMed ID: 27124905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Sequencing Informatics: Challenges and Strategies for Implementation in a Clinical Environment.
    Roy S; LaFramboise WA; Nikiforov YE; Nikiforova MN; Routbort MJ; Pfeifer J; Nagarajan R; Carter AB; Pantanowitz L
    Arch Pathol Lab Med; 2016 Sep; 140(9):958-75. PubMed ID: 26901284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.